ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. Our drug candidates target specific chemokines or chemo-attractant receptors, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected. Our goal is to discover, develop and commercialize therapeutics with distinct advantages over currently marketed therapies in our disease areas of focus, thereby maximizing shareholder value.
4:00 PM ET on Dec 18, 2013
Delayed at least 20 minutes.
Provided by eSignal.
Dec 3, 2013
ChemoCentryx Announces Positive Top-Line CCX168 Phase II Data in ANCA-Associated Renal Vasculitis
Nov 7, 2013
ChemoCentryx Announces Financial Results for the Quarter Ended September 30, 2013
Nov 6, 2013
ChemoCentryx to Present at the 2013 Credit Suisse Annual Health Care Conference
^ Return to Top